Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Journal of Tropical Life Science : International Journal of Theoretical, Experimental, and Applied Life Sciences Heart Science Journal
Icha Farihah Deniyati Faratisha
Brawijaya University
Agriculture, Biological Sciences & Forestry Environmental Science Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Efficacy and Safety of Apixaban vs. Warfarin in Atrial Fibrillation Patients: Systematical Review and Meta-Analysis Mokhamad Fahmi Rizki Syaban; Khadijah Cahya Yunita; Icha Farihah Deniyati Faratisha; Nabila Erina Erwan; Yoga Waranugraha; Adrian Rizal
Heart Science Journal Vol 3, No 1 (2022): Assesment and Outcome of Coronary Artery Disease in the Reperfusion Era
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2022.003.01.5

Abstract

Background: Various treatment strategies to treat AF and reduce its complications have been developed, including anticoagulant administration. Non-Vitamin K antagonist oral anticoagulants (NOAC) are recommended by current guidelines. Different anticoagulants revealed different safety and efficacy characteristic. The real-world evidence-based recommendation is still needed to improve AF management. This study aimed to disclose apixaban safety and efficacy profile compared with warfarin in a real-world population.Methods: We collected data from articles around the world studies comparing Apixaban and Warfarin in NVAF patients recorded online from studies published around 2015 to 2020 that we were taking from a scientific database such as Embase ProQuest, PubMed, and Cochrane based on inclusion criteria. Data analysis was carried out using Review Manager Version 5.4.1 (Cochrane, Copenhagen, Denmark) using Mantel-Haenzel statistical method for categorical data to measure Relative Risk (RR) and 95% Confident Interval (CI). We use a random-effect analysis model if P for heterogeneity (pHet <0.1) and a fixed-effect analysis model if pHet ≥0.1.Results: Apixaban show a benefit in preventing ischemic stroke (RR = 0.51; 95% CI=0.40-0.66; p = <0.00001) ischemic stroke/systemic embolism (RR = 0.63; 95% CI=0.50-0.81; p = <0.0002), and all-cause mortality (RR = 0.54; 95% CI=0.40-0.74; p = <0.0001) relative to Warfarin. Apixaban also show benefit to prevent major bleeding (RR = 0.49; 95% CI=0.41-0.58; p = <0.0001), GI bleeding (RR = 0.46; 95% CI=0.36-0.60; p = <0.0001), and intracranial hemorrhage (RR = 0.45; 95% CI=0.36-0.57; p = <0.0001) relative to Warfarin.Conclusions: Apixaban is over warfarin in efficacy and safety. Apixaban has a safer profile in reducing the risk of major bleeding, GI bleeding, and intracranial hemorrhage in AF patients. 
Molecular Docking and Interaction Analysis of Propolis Compounds Against SARS-CoV-2 Receptor: Propolis Compound Against SARS-CoV-2 Receptor Mokhamad Fahmi Rizki Syaban; Icha Farihah Deniyati Faratisha; Khadijah Cahya Yunita; Nabila Erina Erwan; Dedy Budi Kurniawan; Gumilar Fardhani Ami Putra
Journal of Tropical Life Science Vol. 12 No. 2 (2022)
Publisher : Journal of Tropical Life Science

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/jtls.12.02.08

Abstract

Background: For many people, especially in developing countries, herbal medicine is the most traditional drug choice to treat all diseases including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection). Propolis is one of the popular herbal medicine which has various health benefits, particularly antiviral activity. In this molecular docking study, this investigation examined twenty-five kinds of propolis to bind SARS-CoV-2 protein with the main targets of ACE-2 and M-Pro receptors. Method: Propolis ligands were downloaded from PubChem, meanwhile ACE-2 and M-Pro receptors were downloaded from Protein Data Bank. Both ligands and targets were optimized by Pymol. The pharmacokinetic analysis was conducted using SwissADME. Molecular docking was done using PyRx 0.9 and its binding interaction was visualized by Discovery Studio. To predict the potential inhibition, this study compared the ligand-protein complex of propolis to ligands from the previous study. Result: Through the Lipinski rule, only five of twenty-five types of propolis were not qualified for the criterion. The ability to bind protein targets were various between ligands, the highest affinity to ACE-2 receptors were abietic acid, galangin, chrysin, kaempferol and acacetin, respectively. The binding affinity between ligand and M-Pro were seen weaker than ACE-2 receptor, while the strongest were kaempferol, abietic acid, acacetin, galangin and chrysin, respectively. Conclusion:  Kaempferol is the most potent form of propolis to bind to ACE-2 and M-Pro receptors by assessing the binding affinity and the amount of amino acid residue formation when compared to control ligands. Keywords: ACE-2 receptor, COVID-19, Main protease, Molecular docking, Propolis, SARS-CoV-2
Co-Authors Adrian Rizal Dedy Budi Kurniawan Gumilar Fardhani Ami Putra Khadijah Cahya Yunita Mokhamad Fahmi Rizki Syaban Mokhamad Fahmi Rizki Syaban Nabila Erina Erwan Yoga Waranugraha